X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
macitentan (172) 172
index medicus (93) 93
humans (83) 83
pulmonary arterial hypertension (67) 67
bosentan (63) 63
pulmonary hypertension (53) 53
hypertension, pulmonary - drug therapy (47) 47
endothelin (46) 46
pharmacology & pharmacy (45) 45
endothelin receptor antagonist (43) 43
female (36) 36
male (33) 33
pharmacokinetics (32) 32
ambrisentan (31) 31
cardiac & cardiovascular systems (31) 31
treatment outcome (28) 28
hypertension (27) 27
pyrimidines - therapeutic use (27) 27
endothelin receptor antagonists (26) 26
sulfonamides - therapeutic use (26) 26
adult (25) 25
animals (24) 24
hypertension, pulmonary - physiopathology (24) 24
middle aged (24) 24
pulmonary arterial-hypertension (24) 24
respiratory system (23) 23
double-blind (22) 22
endothelin receptor antagonists - therapeutic use (22) 22
therapy (22) 22
pyrimidines - pharmacology (21) 21
sulfonamides - pharmacology (21) 21
safety (20) 20
survival (20) 20
pharmacology (19) 19
pyrimidines - administration & dosage (19) 19
sulfonamides - administration & dosage (19) 19
sildenafil (18) 18
expression (17) 17
fibrosis (17) 17
pyrimidines - adverse effects (16) 16
riociguat (16) 16
sulfonamides - adverse effects (16) 16
aged (15) 15
care and treatment (15) 15
drug therapy (15) 15
pyrimidines - pharmacokinetics (15) 15
sulfonamides - pharmacokinetics (15) 15
diagnosis (14) 14
endothelin receptor antagonists - pharmacology (14) 14
endothelin-1 (14) 14
analysis (13) 13
antihypertensive agents - therapeutic use (13) 13
research (13) 13
bosentan therapy (12) 12
dose-response relationship, drug (12) 12
endothelin-receptor antagonist (11) 11
healthy-subjects (11) 11
hypertension, pulmonary - diagnosis (11) 11
pharmacodynamics (11) 11
tadalafil (11) 11
young adult (11) 11
cardiovascular system (10) 10
efficacy (10) 10
hemodynamics (10) 10
medicine (10) 10
medicine, general & internal (10) 10
medicine, research & experimental (10) 10
arterial-hypertension (9) 9
cardiovascular (9) 9
cells (9) 9
disease (9) 9
disease progression (9) 9
endothelin a receptor antagonists (9) 9
endothelin receptor antagonists - adverse effects (9) 9
mortality (9) 9
patients (9) 9
pulmonary arteries (9) 9
cancer (8) 8
combination therapy (8) 8
complications and side effects (8) 8
drug interactions (8) 8
endothelin receptor antagonists - administration & dosage (8) 8
prostacyclin (8) 8
pyridazines - therapeutic use (8) 8
pyrimidines - blood (8) 8
sulfonamides - blood (8) 8
treprostinil (8) 8
blood-pressure (7) 7
chemistry, medicinal (7) 7
clinical trials (7) 7
disease models, animal (7) 7
endothelin 1 (7) 7
endothelin b receptor antagonists (7) 7
inhaled iloprost (7) 7
original (7) 7
pathogenesis (7) 7
phenylpropionates - therapeutic use (7) 7
prognosis (7) 7
pulmonary artery - drug effects (7) 7
pulmonary artery - physiopathology (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation. Cardiovascular quality and outcomes, 05/2019, Volume 12, Issue 5, p. e005095
Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and... 
rare diseases | hypertension, pulmonary | macitentan | prognosis | survival
Journal Article
Chest, ISSN 0012-3692, 10/2018, Volume 154, Issue 4, pp. 848 - 861
Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial... 
symptoms | patient-reported outcomes | macitentan | pulmonary arterial hypertension
Journal Article
International Journal of Applied Pharmaceutics, ISSN 0975-7058, 2018, Volume 10, Issue 5, pp. 81 - 89
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 05/2019, Volume 850, pp. 126 - 134
Studies on the role of Rho-associated protein kinase (ROCK) in experimental pulmonary artery hypertension (PAH) relies mainly on the use of pharmacological... 
Vascular remodeling | Macitentan | Rho kinase | Monocrotaline | Pulmonary hypertension | Right ventricle systolic pressure | PROTEIN-KINASE | MODEL | DISCOVERY | FASUDIL | POTENT | Y-27632 | ARTERIAL-HYPERTENSION | PHARMACOLOGY & PHARMACY | PROGRESSION | BOSENTAN | Protein kinases | Health aspects | Analysis
Journal Article
European Respiratory Review, ISSN 0905-9180, 12/2017, Volume 26, Issue 146, p. 170105
For patients with chronic thromboembolic pulmonary hypertension (CTEPH), the current standard of care involves surgical removal of fibro-thrombotic... 
DIAGNOSIS | ANGIOPLASTY | RESPIRATORY SYSTEM | PREDICTORS | RIOCIGUAT | FOLLOW-UP | EXPERIENCE | MACITENTAN | PERFUSION | ENDARTERECTOMY | HEMODYNAMICS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 05/2016, Volume 2016, Issue Issue 1, pp. 1675 - 1682
Thomas J Monaco,1 Carlos D Davila2 1Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, 2Department of Medicine,... 
macitentan | endothelin receptor antagonist | pulmonary arterial hypertension
Journal Article
Circulation Journal, ISSN 1346-9843, 2016
Background:Macitentan is a novel, dual endothelin receptor antagonist with sustained receptor binding, used for the long-term treatment of pulmonary arterial... 
Macitentan | Pulmonary arterial hypertension | Hemodynamics | Safety | Endothelin receptor antagonist
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 07/2019, Volume 855, pp. 124 - 136
In the pulmonary vasculature there is clearance of endothelin-1 from the circulation mediated by endothelin ET receptors. This study explored the haemodynamic... 
Endothelin clearance | Macitentan | Bosentan | Endothelin-1 | ET1-Receptor antagonists | Sarafotoxin S6C | Pulmonary vascular constriction | Hindquarter vascular constriction | Ambrisentan | ETB RECEPTORS | CIRCULATING ENDOTHELIN-1 | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | BLOCKADE | Antihypertensive drugs | Endothelin
Journal Article
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, ISSN 1941-7705, 05/2019, Volume 12, Issue 5
BACKGROUND: Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and... 
CARDIAC & CARDIOVASCULAR SYSTEMS | survival | pulmonary | ALPHA | prognosis | rare diseases | THERAPY | REVEAL REGISTRY | macitentan | CLINICAL-TRIALS | OUTCOMES | hypertension | BOSENTAN
Journal Article
JACC: Heart Failure, ISSN 2213-1779, 2015, Volume 3, Issue 1, pp. 1 - 8
Abstract Objectives This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension... 
Cardiovascular | hospitalization | macitentan | pulmonary arterial hypertension
Journal Article
JOURNAL OF HEART AND LUNG TRANSPLANTATION, ISSN 1053-2498, 02/2019, Volume 38, Issue 2, pp. 194 - 202
BACKGROUND: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50%... 
clinical trial | SURGERY | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | tadalafil | hospitalization | EPOPROSTENOL | ambrisentan | GUIDELINES | MACITENTAN | CLINICAL EVENTS | TRANSPLANTATION | RESPIRATORY SYSTEM | combination therapy | OUTCOMES | pulmonary arterial hypertension | BOSENTAN
Journal Article
ARTHRITIS RESEARCH & THERAPY, ISSN 1478-6354, 10/2016, Volume 18
Background: Systemic sclerosis (SSc) is characterized by early vascular abnormalities and subsequent fibroblast activation to myofibroblasts, leading to... 
EndoMT | FIBROSIS | CELLS | Macitentan | PULMONARY-HYPERTENSION | FIBROTIC DISEASES | SPLICE VARIANT | Microvascular endothelial cells | RHEUMATOLOGY | RECEPTOR ANTAGONIST | FIBROBLASTS | PATHOGENESIS | GROWTH-FACTOR-BETA | SCLERODERMA | Bosentan | Systemic sclerosis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.